Curcumin in Pediatric Inflammatory Bowel Disease

Completed · Phase 1

Conditions studied: Inflammatory Bowel Disease, Ulcerative Colitis, Crohn's Disease

In brief

This is a single center, open label forced dose titration study designed to determine the tolerability of curcumin in pediatric patients with inflammatory bowel disease (IBD). This study will provide initial tolerability and safety data in pediatric patients with IBD. Twenty patients with IBD in remission or with mild disease (score \<34 on PUCAI or score \<30 on the PCDAI) on sulfasalazine or mesalamine aged 8 to 18 years will be enrolled into this study. Each patient will participate in the study for nine weeks. From this study an appropriate dosage will be determined to proceed with a double blinded placebo controlled study.

Key facts

Study ID

NCT00889161

Run by

Seattle Children's Hospital

People needed

11

Starts

2009-05-01

Expected to finish

2010-06-01

Last updated by the study team

2010-06-22

Who can join

Age: 8 and older, up to 18. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Children and adolescents eight to eighteen years old
• Diagnosis of inflammatory bowel disease (IBD) made by a pediatric gastroenterologist based upon history, physical examination, laboratory/radiological studies and gastrointestinal histology
• Mild disease or in clinical remission based upon PUCAI or PCDAI score (score <34 on the PUCAI or score <30 on the PCDAI)
• Parent/guardian and participant must be able to attend study visits at screening, baseline, and weeks three, six, and nine
• Patient must be on a stable dose of IBD medications for at least 3 months
• Patient must be able to swallow study medication

You may not qualify if…

• Abnormal laboratory values as defined in the protocol
• History of increased gastrointestinal symptoms ("flare") in the last 3 months
• Current use (past use of these medications is not an exclusion) of medications such as azathioprine, methotrexate or 6-mercaptopurine used to treat IBD
• Current use (past use of these medications is not an exclusion) of medications or over-the-counter treatments including but not limited to aspirin, NSAID, botanical treatments (ginger, feverfew, yellow clover, Salix species, Populus species, Betula species, and Gaultheria species), essential fatty acids (flax oil and fish oil). Allowed supplementation includes multivitamin, vitamin D \& calcium, folate and vitamin B12, and Iron.
• Other serious medical conditions such as neurological, liver, kidney, auto- immune or systemic disease.
• History of gastrointestinal surgery or planned gastrointestinal surgery in the future.
• Tobacco, alcohol, or illicit drug abuse
• Planned surgery during the potential study participation time
• Inability to swallow study medication

Where it is running

• Seattle Children's Hosptial — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.